Peter Merkel talks about ADVOCATE, a phase 3 trial finding comparable rates of remission with avacopan versus prednisone treatment in patients with ANCA-associated vasculitis (8:08).
04-06-2020 | EULAR 2020 | Conference coverage | Video
Browse topics
In focus
Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA
Anifrolumab for the treatment of SLE
JAK inhibitor safety: Weighing up the data and understanding the risks
Rituximab and rheumatology practice in the COVID-19 era
Safety snapshot: Upadacitinib in patients with PsA
Repurposing rheumatology drugs for COVID-19
Telemedicine in rheumatology: COVID-19 and beyond
Managing PsA in resource-limited settings
Conferences